Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
Bagsværd, Denmark, 20 September 2024 - Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 ( CB1 ) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. ...
https://www.globenewswire.com/news-release/2024/09/20/2949671/0/en/Novo-Nordisk-A-S-Monlunabant-phase-2a-trial-in-obesity-successfully-completed.html